Notice of Results

RNS Number : 2699H

Oxford Biomedica PLC

17 February 2010

 



For Immediate Release

17 FEBRUARY 2010

OXFORD BIOMEDICA: NOTICE OF FY2009 PRELIMINARY RESULTS

RESULTS DATE: 10 March 2010

Oxford, UK -17 February 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its preliminary results for the twelve months ended 31 December 2009 on Wednesday, 10 March 2010.

Analyst meeting: An analyst briefing will be held at 10:30 am on Wednesday, 10 March 2010 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.

Web cast: Simultaneously to the analyst briefing at 10:30 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please follow link: http://mediaserve.buchanan.uk.com/2010/oxb100310/registration.asp approximately 10 minutes (10:20 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court Buchanan Communications	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector^®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NORGMGMZGNRGGZM